Malignant Ovarian Neoplasm — Trials

Malignant Ovarian Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 684
Recruiting: 385
Ph III recruiting: 46
Growth YoY: +9.8%
Industry share: 37%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.8%
Trials / 1,000 deaths: 53.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (437)

clinicaltrialsPublishedShowing 151–179 of 179 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00748527	Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	terminated	Phase 2	134	Cancer Research UKOTHER	1	Jul 10, 2013	clinicaltrials
NCT00084448	Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer	terminated	Phase 2	—	Gynecologic Oncology GroupNETWORK	1	Jul 9, 2013